
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is positioned for strong growth with recent label updates, potential for $150M in annual revenue, and strong investment in in-house innovation and development of new therapies for high-burden diseases. Their primary revenue driver is their Tyvaso DPI royalty income, with potential for growth in the IPF and PPF segments. MNKD's acquisitions and expansion into the pediatric market show their commitment to providing innovative and convenient therapies for underserved diseases. Valuation based on DCF and probability-adjusted EPS analyses supports their current price target and potential for growth, but investors should be aware of potential risks such as product commercial and supply chain risk. As a result, the rating for MNKD shares is Buy. Overall, MannKind has a strong financial standing and a positive outlook for future growth.
Bears say
MannKind is facing potential competition and challenges to their patent protection, which could weaken their competitive position and limit market potential. Their revenue from Furoscix may also be affected by the recent approval of Boehringer Ingelheim's Jascayd, the first new therapy for IPF in a decade. Clinical and regulatory risks also exist for their pipeline programs, and a negative trial readout or regulatory decision could delay commercialization and limit their market potential.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares